VRDN FY2025 SEC EDGAR DEF 14A #159 of 168 in industry

Viridian Therapeutics, Inc.\DE CEO pay ratio

The CEO earned $6.8M in FY2025 against median worker pay of $439,114 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-17
Industry
Chemicals & Pharmaceuticals
Industry rank
#159/168

Data updated August 2026

Subscribe to Viridian Therapeutics, Inc.\DE CEO pay filing updates (RSS)

CEO-to-worker pay ratio
4:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.8M
Median worker
$439,114

Answer first

Viridian Therapeutics, Inc.\DE's FY2025 CEO total of $6.8M ranks #785 of 1,423 complete filings; its 4:1 pay ratio ranks #1371. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $439,114. Industry placement uses the FY2025 SIC-28 peer cohort (# 159 of 168, 6th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#785
$6.8M of 1,423 FY2025
Ratio rank
#1371
4:1 of 1,423
Industry pct
6th
among the lower quartile of industry peers by pay ratio

How Viridian Therapeutics, Inc.\DE ranks nationally

Viridian Therapeutics, Inc.\DE CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,776,249 45th percentile higher than 45% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Viridian Therapeutics, Inc.\DE vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.8M) against pay ratio (4:1) for Viridian Therapeutics, Inc.\DE (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02069254.34138508.56207762.88277017.11.0:111.8:122.5:133.2:144.0:1CEO total payPay ratio (CEO : median worker)Viridian Therapeutics, Inc.\DE, CEO total pay: 6776249 · Pay ratio (CEO : median worker): 4:1Viridian Therapeutics, Inc.\DEHighwater Ethanol LLC, CEO total pay: 394644 · Pay ratio (CEO : median worker): 4:1Highwater Ethanol LLCRoyalty Pharma plc, CEO total pay: 349893 · Pay ratio (CEO : median worker): 4:1Royalty Pharma plcREX AMERICAN RESOURCES Corp, CEO total pay: 5275200 · Pay ratio (CEO : median worker): 4:1REX AMERICAN RESOURCES CorpCelanese Corp, CEO total pay: 462700 · Pay ratio (CEO : median worker): 5:1Celanese CorpSummit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.
Viridian Therapeutics, Inc.\DE vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Viridian Therapeutics, Inc.\DE's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Viridian Therapeutics, Inc.\DE

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
4:1
FY2025
vs prior FY
-4:1
from FY2024 8:1
CEO $ YoY
+506%
$6.8M latest
Filings shown
2
FY2024–2025
Viridian Therapeutics, Inc.\DE CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $1.1M - $400,174 8:1 -
2025 $6.8M +506% $439,114 4:1 -4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1590750, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
4:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.8M
Companies in Industry
168
vs. Industry Median
Below
#159 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Viridian Therapeutics, Inc.\DE: near-parity Item 402(u) ratio

Viridian Therapeutics, Inc.\DE's FY2025 ratio 4:1 ranks #159 of 168 Chemicals & Pharmaceuticals filers (6th percentile). the CEO earned 4× the median employee ($439,114) in FY2025.

At $439,114 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$6.8M

FY2025 Summary Compensation, below median

Pay Ratio

4:1

Below typical

Viridian Therapeutics, Inc.\DE in the lower Chemicals & Pharmaceuticals third

Viridian Therapeutics, Inc.\DE's FY2025 ratio 4:1 ranks #159 of 168 Chemicals & Pharmaceuticals filers (6th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Viridian Therapeutics, Inc.\DE's $6.8M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #785 and ratio rank #1371 split - treat 4:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.8M
Median Employee Pay
$439,114
Pay Ratio
4:1
Filing Date
2026-04-17

Company Info

Ticker
VRDN
CIK
1590750
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1590750, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Viridian Therapeutics, Inc.\DE's FY2025 ratio 4:1 ranks #159 of 168 Chemicals & Pharmaceuticals filers (6th percentile).

Read with Viridian Therapeutics, Inc.\DE

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Otter Tail Corp · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $16K heavier vs Viridian Therapeutics, Inc.\DE); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Calumet, Inc. /DE · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $23K heavier vs Viridian Therapeutics, Inc.\DE); FLOOR · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Organogenesis Holdings Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.8M (Δ $36K heavier vs Viridian Therapeutics, Inc.\DE); FLOOR · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Hayward Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.7M (Δ $39K lighter vs Viridian Therapeutics, Inc.\DE); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Highwater Ethanol LLC (SIC 28 pole)

Highwater Ethanol LLC stamps FLOOR · MICRO nearest in-SIC by ABS(pay_ratio) to Viridian Therapeutics, Inc.\DE's FLOOR filing.
National dual ranks · #785/#1371

Viridian Therapeutics, Inc.\DE's FY2025 package sits #785 by CEO dollars and #1371 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Viridian Therapeutics, Inc.\DE's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Viridian Therapeutics, Inc.\DE (CIK 1590750), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.